Becton, Dickinson and Company
BDX(NYSE)
Sector: Health Care
Beta Coefficient: 0.87
10 Yr Compound EPS Growth: 11.5%
10 Yr Compound DPS Growth 16.5%
Financial Result Year 2014
Revenues (m) 8,446
Net Income (m) 1,236
EPS 6.25
DPS 2.18
Cash flow per share 9.37
Current yield 1.7%
High Price 142.6 P/E 22.8 DY 1.53%
Low Price 105.2 P/E 16.8 DY 2.07%
Becton Dickinson is one of the premier medical supply and technology companies on the planet.
Becton Dickinson is a global health care company . The company develops, manufactures, and sells medical supplies, devices, laboratory instruments, antibodies, reagents, and diagnostic products through its three segments:
BD Medical (54% of FY 2014 sales)
BD Diagnostics (14%)
and
BD Biosciences. (32%)
International sales account for about 59% of the total.
In mid-2014, the company announced the acquisition of CareFusion, a global provider of automated tools and systems designed to reduce patient medication errors and to prevent care-associated infections.
With the acquisition, while accretive, CareFusion may appear to dilute BD;s strong profit margins (NPM for BD is about 15% while CareFusion is about 11%), but it is anticipated synergies and growth to be a net positive.
Its dividend increases are not only steady but large, typically 10% per year, and the company plans to continue that pattern. Dividend raises, last 10 years: 10 times.
BDX(NYSE)
Sector: Health Care
Beta Coefficient: 0.87
10 Yr Compound EPS Growth: 11.5%
10 Yr Compound DPS Growth 16.5%
Financial Result Year 2014
Revenues (m) 8,446
Net Income (m) 1,236
EPS 6.25
DPS 2.18
Cash flow per share 9.37
Current yield 1.7%
High Price 142.6 P/E 22.8 DY 1.53%
Low Price 105.2 P/E 16.8 DY 2.07%
Becton Dickinson is one of the premier medical supply and technology companies on the planet.
Becton Dickinson is a global health care company . The company develops, manufactures, and sells medical supplies, devices, laboratory instruments, antibodies, reagents, and diagnostic products through its three segments:
BD Medical (54% of FY 2014 sales)
BD Diagnostics (14%)
and
BD Biosciences. (32%)
International sales account for about 59% of the total.
In mid-2014, the company announced the acquisition of CareFusion, a global provider of automated tools and systems designed to reduce patient medication errors and to prevent care-associated infections.
With the acquisition, while accretive, CareFusion may appear to dilute BD;s strong profit margins (NPM for BD is about 15% while CareFusion is about 11%), but it is anticipated synergies and growth to be a net positive.
Its dividend increases are not only steady but large, typically 10% per year, and the company plans to continue that pattern. Dividend raises, last 10 years: 10 times.
No comments:
Post a Comment